IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDEAYA Biosciences (IDYA) has appointed Stu Dorman as Chief Commercial Officer. Dorman brings over 20 years of oncology commercialization experience from Gilead Sciences and Bristol Myers Squibb. At Gilead, as VP of U.S. Oncology, he built a commercial organization achieving billion-dollar global sales. During his 14-year tenure at BMS, he led commercial strategy for key products including Opdivo. The appointment comes as IDEAYA advances its darovasertib trials in first-line HLA-A2(-) MUM and neoadjuvant UM, along with IDE397 development in MTAP-deletion cancers.
IDEAYA Biosciences (IDYA) ha nominato Stu Dorman come Chief Commercial Officer. Dorman porta con sé oltre 20 anni di esperienza nella commercializzazione in oncologia, avendo lavorato per Gilead Sciences e Bristol Myers Squibb. Presso Gilead, come VP dell'oncologia negli Stati Uniti, ha costruito un'organizzazione commerciale che ha raggiunto vendite globali da miliardi di dollari. Durante i suoi 14 anni alla BMS, ha guidato la strategia commerciale per prodotti chiave, tra cui Opdivo. Questa nomina avviene mentre IDEAYA avanza nelle sue sperimentazioni con darovasertib nell'UM neoadiuvante e in MUM HLA-A2(-), insieme allo sviluppo di IDE397 nei tumori con delezione di MTAP.
IDEAYA Biosciences (IDYA) ha nombrado a Stu Dorman como Director Comercial. Dorman aporta más de 20 años de experiencia en la comercialización de oncología de Gilead Sciences y Bristol Myers Squibb. En Gilead, como VP de Oncología en EE. UU., construyó una organización comercial que alcanzó ventas globales de miles de millones de dólares. Durante su mandato de 14 años en BMS, lideró la estrategia comercial de productos clave, incluyendo Opdivo. Esta nombramiento se produce mientras IDEAYA avanza en sus ensayos de darovasertib en HLA-A2(-) MUM de primera línea y UM neoadyuvante, junto con el desarrollo de IDE397 en cánceres con deleción de MTAP.
IDEAYA 바이오사이언스 (IDYA)는 Stu Dorman을 최고 상업 책임자로 임명했습니다. Dorman은 Gilead Sciences와 Bristol Myers Squibb에서 20년 이상의 종양학 상업화 경험을 가지고 있습니다. Gilead에서 그는 미국 종양학 부사장으로서 수십억 달러의 글로벌 매출을 달성하는 상업 조직을 구축했습니다. BMS에서 14년 동안 재직하는 동안, 그는 Opdivo를 포함한 주요 제품의 상업 전략을 이끌었습니다. 이번 임명은 IDEAYA가 1차 HLA-A2(-) MUM 및 수술 전 UM에서 darovasertib 임상 시험을 진행하고, MTAP 결실 암에 대한 IDE397 개발을 진행하면서 이루어졌습니다.
IDEAYA Biosciences (IDYA) a nommé Stu Dorman au poste de Directeur Commercial. Dorman apporte plus de 20 ans d'expérience dans la commercialisation en oncologie, ayant travaillé pour Gilead Sciences et Bristol Myers Squibb. Chez Gilead, en tant que VP de l'oncologie aux États-Unis, il a construit une organisation commerciale ayant atteint des ventes mondiales de plusieurs milliards de dollars. Au cours de ses 14 années chez BMS, il a dirigé la stratégie commerciale pour des produits clés, y compris Opdivo. Cette nomination survient alors qu'IDEAYA avance dans ses essais cliniques avec le darovasertib dans l'UM néoadjuvant et dans MUM HLA-A2(-), ainsi que le développement de l'IDE397 dans les cancers avec délétion de MTAP.
IDEAYA Biosciences (IDYA) hat Stu Dorman zum Chief Commercial Officer ernannt. Dorman bringt über 20 Jahre Erfahrung in der Kommerzialisierung von Onkologie von Gilead Sciences und Bristol Myers Squibb mit. Bei Gilead baute er als VP der US-Onkologie eine kommerzielle Organisation auf, die globale Verkäufe in Milliardenhöhe erzielte. Während seiner 14-jährigen Tätigkeit bei BMS leitete er die kommerzielle Strategie für wichtige Produkte, einschließlich Opdivo. Die Ernennung erfolgt, während IDEAYA seine darovasertib-Studien in der Erstlinie HLA-A2(-) MUM und neoadjuvantem UM vorantreibt, sowie die Entwicklung von IDE397 bei MTAP-deletionsbezogenen Krebserkrankungen.
- Appointment of experienced commercial leader with proven track record in billion-dollar oncology products
- Strategic timing aligns with advancement of potential registrational trials
- Executive brings successful launch experience with major cancer treatments
- None.
- Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®
"We are thrilled to welcome Stu as IDEAYA makes continued enrollment progress in the potential registrational trial for darovasertib in first-line HLA-A2(-) MUM, and the potential indication expansion opportunity in neoadjuvant UM. Stu has extensive commercial experience in global product commercialization, product launches, sales and market access. Most importantly, Stu's proven track record in maximizing the commercial opportunity for several global blockbuster cancer treatments, such as Trodelvy® and Opdivo®, makes him an ideal fit to lead our commercial organization," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
"I am delighted to join IDEAYA to build an industry-leading commercial organization that is well positioned to deliver potential first-in-class precision medicine oncology therapies that can improve the lives of cancer patients worldwide. I look forward to leveraging my extensive commercial oncology experience as darovasertib continues to make progress in the potential registrational trial in first-line HLA-A2(-) MUM and targeted Phase 3 start in neoadjuvant UM, and as the broader clinical pipeline advances, including IDE397 in MTAP-deletion non-small cell lung cancer and urothelial cancer," commented Mr. Dorman.
Prior to joining IDEAYA, Mr. Dorman was the Vice President,
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the Company's potential commercialization of darovasertib and other product candidates in IDEAYA's clinical pipeline and Mr. Dorman's impact on IDEAYA's business. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-stu-dorman-as-chief-commercial-officer-302307574.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
Who is the new Chief Commercial Officer at IDEAYA Biosciences (IDYA)?
What is IDEAYA Biosciences (IDYA) currently developing in clinical trials?
What was Stu Dorman's previous role before joining IDEAYA Biosciences (IDYA)?
